<DOC>
	<DOCNO>NCT01517035</DOCNO>
	<brief_summary>Background : - People kind cancer benefit donate bone marrow stem cell . These stem cell help produce healthy bone marrow slow stop spread abnormal cell . However , stem cell transplant always work . Also , may serious side effect cause illness death . The Bone Marrow Stem Cell Transplant Program study method make stem cell transplant procedure safer effective . Objectives : - To test new procedure may improve success decrease side effect stem cell transplant . Eligibility : - Individuals 10 75 year age life-threatening illness may require stem cell transplant . - Healthy sibling able provide stem cell transplant . Design : - Participants screen medical history , physical exam , blood urine test . - Donor procedure : - Stem cell donor start apheresis donate white blood cell . - Donors receive filgrastim shot 5 day help move stem cell blood collection . - Donors another round apheresis donate stem cell transplant . - Recipient procedure : - Before transplant , recipient radiation twice day 3 day chemotherapy 7 day . - After radiation chemotherapy , recipient receive stem cell provide donor . - After transplant , recipient receive white blood cell provide donor . - Recipients monitor closely 4 month study success transplant . They followup visit least yearly thereafter . - Recipients research apheresis prior transplant 3 month .</brief_summary>
	<brief_title>Improving Blood Stem Cell Collection Transplant Procedures</brief_title>
	<detailed_description>Peripheral blood stem cell transplant research carry NHLBI BMT Unit focus transplant technique design decrease graft versus host disease ( GVHD ) , increase graft-versus-leukemia ( GVL ) effect reduce risk post-transplant graft rejection . Through incremental transplant clinical trial show control stem cell ( CD34+ cell ) T lymphocyte ( CD3+ cell ) dose , severe GVHD reduce whilst beneficial GVL effect preserve . We find T cell deplete transplant use Nexell/Baxter Isolex 300i system subsequently , Miltenyi CD34+ CliniMACs system obtain high CD34+ dos deplete lymphocyte safe administer associate less severe acute GVHD promising response rate overall survival . Our previous trial help u create transplant environment ( significant lymphodepletion minimal post transplant immunosuppression ) make ideal platform adoptive cellular immunotherapy This protocol design evaluate safety efficacy improve ex vivo graft manipulation procedure use Miltenyi CliniMACs CD 34 , 3 19 selection system HLA-matched sibling allogeneic peripheral blood stem cell transplant . The manipulation graft primary research intervention aspects clinical management protocol standard care . The target CD34+ dose range 3 time 10 ( 6 ) /kg 10 time 10 ( 6 ) /kg target CD3+ dose range 5 x 10 ( 4 ) /kg 1 time 10 ( 6 ) /kg . The technique preserve great number NK cell . Once demonstrate adequacy engraftment first ten recipient , plan amendment permit use protocol serve platform several plan adoptive cellular therapy initiative . The protocol accrue 44 subject age 10-75 hematological malignancy HLA-matched sibling donor , allogeneic stem cell transplantation HLA-matched sibling would routinely indicate . Diagnostic category include acute chronic leukemia , myelodysplastic syndrome , lymphoma , multiple myeloma myeloproliferative syndrome . Subjects receive myeloablative conditioning regimen cyclophosphamide ( 120 mg/kg total ) , fludarabine ( 125 mg/m ( 2 ) total ) total body irradiation ( 1200 cGy lung shield 600 cGy ) , follow infusion stem cell product prepare use Miltenyi CliniMACS system CD34 , 3 &amp; 19 selection . Older subject receive low dose irradiation ( 600 cGy ) without lung shield reduce regimen intensity . The overall objective ass feasibility use system platform cellular immunotherapy initiative . The primary study endpoint overall survival day plus 200 . Non-relapse mortality day plus 200 monitor safety . Secondary endpoint standard transplant outcome variable non-hematologic toxicity , incidence severity acute chronic GVHD relapse disease .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients remission well patient primary induction failure refractory disease consider inclusion . At discretion PI , patient may continue standard care treatment option control baseline disease burden start protocol . RECIPIENT Ages 1075 year inclusive Chronic myelogenous leukemia ( CML ) : Subjects age 21 chronic phase Subjects age 1075 chronic phase fail treatment imatinib , intolerance imatinib , receive imatinib therapeutic dos within first 12 month diagnosis . Subjects age 1075 accelerated phase blast transformation . Acute lymphoblastic leukemia ( ALL ) : category : ALL first remission highrisk feature ( present leukocyte count &gt; 100,000/cu mm , Karyotypes t9 ; 22 , t4 , t19 , t11 , biphenotypic leukemia ) All second subsequent remission , primary induction failure , partially respond untreated relapse . Acute myelogenous leukemia ( AML ) : AML first remission except AML good risk karyotype : AML M3 ( t15 ; 17 ) , AML M4Eo ( inv 16 ) , AML ( 8 ; 21 ) . All AML second subsequent remission , primary induction failure resistant relapse . Myelodysplastic syndrome ( MDS ) : category refractory anemia transfusion dependence , refractory anemia excess blast , transformation acute leukemia , chronic myelomonocytic leukemia , atypical MDS/myeloproliferative syndrome . Myeloproliferative disorder include atypical ( Ph negative ) chronic myeloid neutrophilic leukemia , progress myelofibrosis , polycythemia vera , essential thrombocythemia transformation acute leukemia progressive transfusion requirement pancytopenia . Chronic lymphocytic leukemia refractory fludarabine treatment bulky progressive disease thrombocytopenia ( less equal 100,000/ microl ) anemia ( less equal 10g/dl ) due recent chemotherapy . NonHodgkin lymphoma include Mantle cell lymphoma relapse refractory standard care treatment . Multiple myeloma , Waldenstroms macroglobulinemia , unresponsive relapse follow standard care treatment . HLA identical ( 6/6 ) relate donor . For adult : Ability comprehend investigational nature study provide inform consent . For minor : write informed consent one parent guardian . Informed oral consent minor : process explain minor level complexity appropriate age ability comprehend . DONOR Related donor , HLA identical ( 6/6 ) recipient Weight great equal 18 kg Age great equal 2 less equal 80 year old For adult : Ability comprehend investigational nature study provide inform consent . For minor : Written inform consent one parent guardian inform assent : The process explain minor level complexity appropriate age ability comprehend . EXCLUSION CRITERIA : RECIPIENT ( follow ) Estimated probability survive less three month Major anticipate illness organ failure incompatible survival transplant Severe psychiatric illness . Mental deficiency sufficiently severe make compliance transplant treatment unlikely make informed consent impossible . Positive pregnancy test woman childbearing age . HIV positive DLCO adjust Hb ventilation &lt; 50 % predict Left ventricular ejection fraction &lt; 40 % ( evaluated ECHO ) &lt; 30 % ( evaluated MUGA ) AST/SGOT &gt; 10 time ULN ( &gt; grade 3 , CTCAE ) Bilirubin &gt; 5 time ULN ( &gt; grade 3 , CTCAE ) Creatinine &gt; 4.5 time ULN ( &gt; grade 3 , CTCAE ) Prior allogeneic stem cell transplantation DONOR ( follow ) Pregnant breastfeeding . Lactating donor permit provided breastmilk discard day filgatrim ( GCSF ) give . Unfit receive GCSF undergo apheresis ( abnormal blood count , history stroke , uncontrolled hypertension ) Sickling hemaglobinopathy include HbSS , HbAS , HbSC Donors positive HIV active hepatitis B ( HBV ) , hepatitis C ( HCV ) human Tcell lymphotropic virus ( HTLVI/II ) Severe psychiatric illness . Mental deficiency sufficiently severe make compliance BMT treatment unlikely , make informed consent impossible . Age great equal 80 year old Children weigh less equal 18 kg &lt; 2 year age .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 29, 2017</verification_date>
	<keyword>Peripheral Blood Stem Cell Transplantation</keyword>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>Transplant</keyword>
	<keyword>Myelodyplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Leukemia</keyword>
</DOC>